本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Viking Therapeutics, Inc.

27.94
-0.1500-0.53%
盘后27.960.0200+0.07%19:56 EST
成交量:319.02万
成交额:8,836.64万
市值:31.36亿
市盈率:-27.70
高:28.30
开:28.18
低:26.97
收:28.09
数据加载中...
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Greg Zante拟减持16136股,总价约92.2万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Brian Lian拟减持115,859股,总价约667万美元
2024/07/30

关联方拟减持公告

Form144 | Viking Therapeutics高管Marianna Mancini拟减持18026股,总价约102.99万美元
2024/07/25

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/25

重要事件披露

Form 8-K - Current report
2024/06/04

重要事件披露

Form 8-K - Current report
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2024/05/23

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments